Anzeige
Mehr »
Samstag, 28.02.2026 - Börsentäglich über 12.000 News

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A41HQ7 | ISIN: US80512Q5018 | Ticker-Symbol: 80W
NASDAQ
27.02.26 | 17:59
0,909 US-Dollar
-9,98 % -0,101
Branche
Software
Aktienmarkt
Sonstige
1-Jahres-Chart
NEXENTIS TECHNOLOGIES INC Chart 1 Jahr
5-Tage-Chart
NEXENTIS TECHNOLOGIES INC 5-Tage-Chart

Aktuelle News zur NEXENTIS TECHNOLOGIES Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MiN2OFF, Inc. - 8-K, Current Report-
NEXENTIS TECHNOLOGIES Aktie jetzt für 0€ handeln
MiN2OFF Inc.: N2OFF Announcing Corporate Rebranding as Nexentis Technologies - Innovative AI and Data Driven Computational Biotech Company57New identity reflects Company's evolution into an innovative data driven biotech company leveraging MITOLINE and mitochondrial carrier biology across oncology and inflammatory metabolic diseases Neve...
► Artikel lesen
20.02.Plantify Foods Inc (2): Plantify holder N2OFF's shareholdings decrease to 14.6%2
19.02.Plantify Foods, Inc.: N2OFF, Inc. Provides Early Warning Disclosure2
12.02.N2OFF Inc.: MitoCareX Bio Reports Successful Results in Vitro: MITOLINE-Powered Small Molecules Show Anti-Inflammatory Potential for Metabolic Syndrome-Related Diseases103MITOLINE Algorithm Powers Development of First-in-Class Small Molecules Targeting a Mitochondrial Carrier for Inflammatory Metabolic Diseases - A Market Projected to Exceed $120 billion by 2030 Neve...
► Artikel lesen
02.02.N2OFF Inc.: In Spaceflight Conditions: N2OFF's MitoCareX Bio Highlights Co-Founder's Innovative Research on Mitochondrial Carriers in Microgravity and Cosmic radiation Conditions1
22.01.N2OFF Inc.: MitoCareX Bio Announces Positive In Vitro Results from Its Mitochondrial Carrier Small Molecule Platform162MITOLINE Algorithm Powers Development of First-in-Class Small Molecules Targeting a Mitochondrial Carrier for Inflammatory Metabolic Diseases - A Market Projected to Exceed $120 billion by 2030 Neve...
► Artikel lesen
15.01.N2OFF Inc.: MitoCareX Bio Spotlights Co-Founder's Pioneering Research on Mitochondrial Carriers in Spaceflight Stress Conditions2
12.01.N2OFF vergütet Berater für Investor Relations mit 35.000 Aktien2
12.01.N2OFF, Inc. - 8-K, Current Report-
05.01.N2OFF treibt europäisches Solarportfolio mit Meilenstein bei deutschem Projekt voran3
05.01.N2OFF advances European solar portfolio with key German project milestone2
05.01.N2OFF Inc.: N2OFF Advances $340,000 Payment to Gain Better Terms in Flag Solar Energy Initiative, Reflecting Approximately an Additional $1.7 Million in Project Profit Stake2
29.12.25N2OFF advances European solar portfolio with key milestones in Germany, Italy1
29.12.25N2OFF Inc.: N2OFF Accelerates European Renewable Energy Momentum with Major De-Risking Milestones and Approximately $1.69 Million Value Unlock in Germany and Italy459Neve Yarak, Israel, Dec. 29, 2025 (GLOBE NEWSWIRE) -- N2OFF, Inc. (NASDAQ: NITO) ("N2OFF" and the "Company"), a cleantech company investing in solar energy assets based on the RTB (Ready to Build)...
► Artikel lesen
16.12.25N2OFF, Inc. - 8-K, Current Report-
18.11.25N2OFF Inc.: MitoCareX Identifies Hit Compounds and Targets Preclinical Candidate Nomination231Neve Yarak, Israel, Nov. 18, 2025 (GLOBE NEWSWIRE) -- N2OFF, Inc. (NASDAQ: NITO) ("N2OFF"), a cleantech company investing in solar energy assets based on the RTB (Ready to Build) business model, following...
► Artikel lesen
13.11.25N2OFF, Inc. - 10-Q, Quarterly Report-
30.10.25N2OFF Inc.: N2OFF Completed Merger with Cancer Drug Discovery Company Targeting Tough-to-Treat Pancreatic and Lung Cancers291Neve Yarak, Israel, Oct. 30, 2025 (GLOBE NEWSWIRE) -- N2OFF, Inc. (NASDAQ: NITO) ("N2OFF" and the "Company"), a cleantech company investing in solar energy assets based on the RTB (Ready to Build)...
► Artikel lesen
23.10.25SciSparc sells majority-owned cancer therapy subsidiary to N2OFF1
Weiter >>
49 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1